Morningstar

Medpace Holdings Inc MEDP

Morningstar Rating
Unlock
Stock XNAS Rating as of
$537.92 +8.69 (1.64%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Medpace Faces Elevated Cancelations and Weak Gross Bookings; Replenishing Backlog Will Be Key

Rachel Elfman

Medpace is a global late-stage contract research organization, or CRO, that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. The company was founded over 30 years ago in Cincinnati. It is principally based in the US but also operates in Europe, Asia, South America, Africa, and Australia.

Read Full Report

Price vs Fair Value

View History
MEDP is trading within a range we consider fairly valued.
Price
$529.23
Fair Value
H<w
Uncertainty
LOCK|wT^?
1-Star Price
LOCK|j.^j
5-Star Price
LOCK|S.qP
Economic Moat
LOCK|@!!F
Capital Allocation
LOCK|%&wKz%

Bulls Say, Bears Say

Bulls

Medpace's small and midsize biopharma customers are very dependent on outsourced clinical trials since they do not have the capacity to run trials in-house.

Bears

Significant pullbacks in biotech funding or declines in outsourcing penetration rates have a material impact on Medpace's growth.

Show More

News

View All

Trading Information

Previous Close Price
$529.23
Day Range
$528.21–540.11
52-Week Range
$306.70–628.92
Bid/Ask
$452.40 / $566.15
Shares Outstanding
28.56M
Market Cap
$15.36B
Volume/Avg
260,356 / 374,108

Key Statistics

Price/Earnings (Normalized)
33.26
Price/Sales
5.72
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
3.61%

Company Profile

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
6,300
Website
https://www.medpace.com

Competitors

Valuation

View More
Metric
MEDP
FTRE
ICLR
Price/Earnings (Normalized)
 33.26133.9714.85
Price/Book Value
 25.263.221.42
Price/Sales
 5.720.611.62
Price/Cash Flow
 24.2346.8512.71
Price/Earnings
MEDP
FTRE
ICLR

Financial Strength

Metric
MEDP
FTRE
ICLR
Quick Ratio
 0.780.831.09
Current Ratio
 0.850.951.14
Interest Coverage
 —−4.071.90
Quick Ratio
MEDP
FTRE
ICLR

Profitability

Metric
MEDP
FTRE
ICLR
Return on Assets (Normalized)
 25.67%1.90%4.63%
Return on Equity (Normalized)
 113.08%8.61%8.15%
Return on Invested Capital (Normalized)
 86.20%7.82%7.13%
Return on Assets
MEDP
FTRE
ICLR

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
LOCK|>@NB>#B#LOCK|%g$199B
 Danaher Corp
DHR
LOCK|PmjLY!q&LOCK|x<$142B
 IDEXX Laboratories Inc
IDXX
LOCK|bVbS<w^%LOCK|P>?$44B
 Agilent Technologies Inc
A
LOCK|w!%RllhLOCK|bS$38B
 Waters Corp
WAT
LOCK|vt@j?&LOCK|^#$37B
 IQVIA Holdings Inc
IQV
LOCK|rtt>?#LOCK|Yg@>C$35B
 Illumina Inc
ILMN
LOCK|$Fk#<mqLOCK|dg!&$28B
 Mettler-Toledo International Inc
MTD
LOCK|DBqwpsFLOCK|dk$d$27B
 Quest Diagnostics Inc
DGX
LOCK|zmr!M%LOCK|@ywj$$22B
 Labcorp Holdings Inc
LH
LOCK|@sDRf!qjLOCK|$Hxd$22B

Sponsor Center